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Background: A remolded microenvironment in hepatocellular carcinoma (HCC) caused by abnormally expressed
matricellular proteins could promote HCC progression. The cell-matrix interactions mediated by integrins play an
important role in tumor microenvironment. Epidermal Growth Factor-like repeats and Discoidin I-Like Domains 3
(EDIL3), an extracellular matrix (ECM) protein with angiogenic and anti-inflammatory effects, is abnormally highly
expressed in HCC. Here we aim to analyze its expression in liver and HCC tissues, investigate the underlined
mechanisms accounted for HCC progression.
Methods: EDIL3 expression level is examined in normal liver, cirrhotic liver and HCC at both mRNA and protein level.
The association between EDIL3 and clinical outcomes is analyzed. The pattern of EDIL3 expression and location is
examined using Immunofluorescence and ELISA. Overexpression or knock-down of EDIL3 in a panel of cell lines are
subjected to assays related to proliferation, invasion, and anoikis to investigate the mechanisms of this matrix protein in
HCC progression. Recombinant EDIL3 treatment is applied to confirm the results.
Results: Compared with normal liver and cirrhotic liver, EDIL3 is elevated in HCC. High level of EDIL3 protein is
much more commonly in patients with larger tumor or portal vein tumor thrombus (PVTT) formation, associated
with poor prognosis. EDIL3 is abundantly expressed in HCC cells and secreted by cancer cells. In vitro and in vivo
studies indicate that EDIL3, probably in an autocrine manner, inhibits anoikis and promotes anchorage-independent
growth of HCC cells. Further mechanistic studies suggest integrin ligation by EDIL3 and thus that the sustained
activation of the FAK-Src-AKT signal is responsible for the anoikis resistance and anchorage independence. Both the
administration of cilengitide, a RGD-containing integrin antagonist, and silencing of integrin αV, an important
RGD-binding integrin, results in the blockade of anoikis-resistance induced by EDIL3.
Conclusion: Our study suggests that high levels of autocrine EDIL3 may contribute to a receptive microenvironment
for the survival of detached HCC cells and may involve in cancer cell spreading. We also highlight the importance of
interaction between EDIL3 and integrin αV and suggest disrupting the ligation of EDIL3 to integrins via RGD-blocking
in selected patients may bear potential therapeutic value.
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Hepatocellular carcinoma (HCC) is a lethal disease with
high mortality due to the high rate of postoperative
recurrence and metastasis [1]. Both genetic and epigen-
etic alterations [2] within the HCC and a remolded
microenvironment [3,4] surrounding HCC affect the
biological behaviors of HCC and thus result in different
outcomes of HCC patients. Extracellular matrix (ECM)
proteins are the main non-cellular components of the
tumor microenvironment; many of them can interact
with the tumor cell through direct binding to specific
receptors or by modulating the activation of other cytokines
[5,6]. Some reports have suggested that microenvironmen-
tal changes caused by abnormally expressed matricellular
proteins may modulate HCC progression by affecting cell
growth, migration, invasion, anoikis and metastasis;
thus, targeting ECM proteins may have therapeutic
value [3,7-10].
Epidermal Growth Factor-like repeats and Discoidin
I-Like Domains 3 (EDIL3), also known as DEL-1, is a
secreted ECM protein that was firstly characterized in
vascular morphogenesis [11]. Structurally, EDIL3 con-
tains 3 EGF-like repeats and 2 discoidin-like repeats,
with an RGD motif located in the second EGF-like
repeat [11]. Three-dimensional crystal structures reveal
a unique RGD finger, which is believed to be advantageous
for its ligation with integrins over other RGD-containing
ECM proteins [12]. EDIL3 has been intensively studied in
vascularization, exhibiting strong angiogenic or vasculariz-
ing function through integrin αvβ3 modulation [13,14].
Moreover, this protein plays a role in modulating immu-
nocyte adhesion through interactions with leukocyte-
specific integrins [15]. The role of EDIL3 in cancer is also
revealed in several malignancies, albeit in observational
level. For example in pancreatic carcinoma, EDIL3 is one
of the SHH-dependent stromal factors that predict poor
prognosis [16]; another study focusing on carcinogenesis
of ulcerative colitis-associated colorectal cancer suggests
EDIL3 may add some power in this process [17]; interest-
ingly, EDIL3 could also be detected in exosomes of blad-
der cancer cells and facilitate cancer progression trough
EGFR signal [18]. In the field of HCC, high-throughput
genomic data suggests elevated EDIL3 in HCC compared
with adjacent liver [19], and a clinical analysis reveals that
EDIL3 might affect the prognosis of HCC [20]. However,
no study has addressed how EDIL3 is involved in HCC de-
velopment and progression.
Anoikis is a special apoptotic process resulting from the
loss of or inappropriate cell adhesion. Upon detaching
from the primary lesion, the lack of cell-ECM adhesion
fails to maintain the pro-survival signals within cancer
cells, leading to decreased anti-apoptotic signals, thus
activating anoikis [21]. Gaining anoikis resistance is a
prerequisite for intra-hepatic spreading and extra-hepaticmetastasis of HCC. In addition to adaptive alterations,
such as switch in integrin expression patterns or the
hyperactivation of receptor tyrosine kinases, the abnormal
microenvironment also helps the cancer evading anoikis
[22]. Integrins are the key mediators of the cell-ECM
interaction, sending pro-survival signals in the presence of
ECM ligands, e.g., collagens and laminins, and inducing
apoptosis in their unligated status [23]. EDIL3 is an
important ligand for αV-coupled integrins via RGD
recognition and has been shown to be able to bind
these groups of integrins [24] and inhibit anoikis in the
endothelium [25].
In the present study, we focus on the role of EDIL3 in
HCC and demonstrate that EDIL3 is highly expressed in
HCC patients. Moreover, the accumulation of tumor-
derived EDIL3 in the microenvironment promotes anoikis
resistance and anchorage independent growth advantage
through the activation of integrin signal pathways.
Results
The EDIL3 level is significantly elevated in HCC tissue and
is associated with adverse biological behaviors
To observe the expression change in HCC, we first tested
the EDIL3 level in 5 normal livers (NL), 10 cirrhotic livers
(CL), and 49 HCCs by qRT-PCR and western blot. The
result revealed that EDIL3 was mildly expressed in NLs
and CLs but was significantly elevated in HCC both at the
mRNA and protein level (Figure 1 A, B, Additional file 1:
Figure S1A). IHC stain of another array of samples includ-
ing 3 NLs, 10HCCs and 6 PVTTs confirmed the high
expression of EDIL3 in HCC compared with NL and CL
(Figure 1C). Notably, co-stain of EDIL3 and endothelium
marker CD31 in HCC samples showed EDIL3 is not only
stained with endothelium marker, but also widely and
diffusively located in cancer cells clusters (Figure 1C, D),
suggesting that cancer cells becomes an important sources
of EDIL3 besides endothelium.
We then explored the clinical value of EDIL3 in HCC
by analyzing the protein level in another independent
202 HCC samples gathered on tissue microarrays
(TMA). We observed approximately 72% (57/202) of
patients were EDIL3-positive, and high levels of EDIL3
positivity was significantly associated with adverse clini-
copathological parameters of HCC, including tumor size,
PVTT formation, and TNM stage (Table 1). Moreover,
Kaplan-Meier survival analysis in the 192 patients with
follow-up demonstrated a higher postoperative recur-
rence risk and poor survival in patients with high EDIL3
expression. Because high EDIL3 expression was much
more common in patients with PVTT, we examined
EDIL3 protein levels in 6 PVTT samples. The result
revealed that EDIL3 stain was very strong in all of the
PVTT samples (6/6) as well as microscopic tumor
thrombus (Figure 1C), and this was validated by western
Figure 1 (See legend on next page.)
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Figure 1 EDIL3 is significantly up-regulated in HCC and PVTT compared with normal liver (NL) and cirrhotic livers (CL) and is closely
related to the prognosis of HCC. A, The transcriptional level of EDIL3 is measured via qRT-PCR in 5 NLs, 10 CLs and 49 HCCs. The relative
mRNA level is normalized to β-actin and is presented as Δ–ΔCq. The mRNA of EDIL3 in HCC is significantly higher than both NL and CL; B,
The protein level of EDIL3 in NL, CL, HCC and PVTT was examined by western blot with β-actin as a loading control. The EDIL3/β-actin
densitometry is performed and shown as density value below. EDIL3 is mildly expressed In NL and CL while significantly elevated in HCC and
PVTT; C, Representative pictures demonstrating EDIL3 staining in different liver samples including NL, CL, HCC, PVTT and microscopic thrombi
by IHC. Scale bars, 50 μm or 150 μm; Arrow heads indicate that high EDIL3 expression is largely localized to cancer cells. D, Confocal
microscopic observation of immunofluorescence staining of CD31 (green), an endothelium marker, and EDIL3 (red) in HCC samples show
EDIL3 is not only localized with endothelium, but also widely and diffusively located in cancer cells clusters. White arrows indicates the
endothelium; Grey arrows indicates the cancer cell cluster. E, Kaplan-Meier analysis of overall survival between EDIL3-negative or moderately
positive patients and highly positive patients shows a significant survival advantage in EDIL3 low express group. **: P < 0.01.
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high level of EDIL3 in HCC and suggest its association
with adverse clinicopathological parameters and poor
prognosis.
EDIL3 is abundantly expressed in HCC cell lines and
exhibits unique expression pattern
We examined EDIL3 expression in 7 HCC cell lines and 2
non-HCC cell lines. The mRNA level of EDIL3 varied
among all of the cell lines, with the HCC cell lines Huh-7
and CSQT-2 exhibiting much higher mRNA levels of
EDIL3 (Figure 2A), while THLE-3 and Lo-2, which derivedTable 1 Correlation between EDIL3 and key
clinicopathological parameters
Variables EDIL3 (n = 202)
High Positive Negative P value
Age (years)
≤50 30 43 30
0.829
>50 36 36 27
Gender
Female 7 12 9
0.644
Male 59 67 48
Tumor size
≤5 cm 29 31 41
0.003
>5 cm 37 48 16
Thrombus
No 42 65 51
0.002
Yes 24 14 6
Multiplicity
Single 52 65 51
0.277
Multiple 14 14 6
TNM stage
I 31 40 45
0.010
II 7 10 6
III 27 24 6
IV 1 1 0
The bold numbers represent the P-values with significant differences.from normal hepatocyte, also showed mild transcription.
Surprisingly, inconsistent with mRNA, EDIL3 protein was
detected at almost the same level in the cell lysates of all
the cell lines (Figure 2A) and the Immunofluorescence
confirmed the existence of EDIL3 in cytoplasm of all 9 cell
lines (Figure 2C and Additional file 1: Figure S1). Indeed,
we also observed this inconsistency in other cancer cell
lines (Additional file 2: Figure S2). Because EDIL3 is an
ECM protein, we examined the EDIL3 that was secreted in
conditioned medium (CM). All cell lines were subjected to
standardized condition (see methods for details), and the
secreted proteins in the CM was analyzed by Western Blot
and ELISA. Not surprisingly, the Huh-7 and CSQT-2
secreted the most EDIL3 into the CM, whereas there was
only detectable EDIL3 in the CM of other cell lines
(Figure 2A, B). These observations in cell lines reveal a
unique autocrine expression pattern of EDIL3, and the high
level of EDIL3 in CSQT-2, a PVTT derived cell line, is
consistent with the observation in patient’s samples above.
Autocrine EDIL3 promotes anoikis resistance and
anchorage-independent growth in HCC cells in vitro
Anoikis resistance and invasion are two important features
of the HCC cells that are prone to forming PVTT or
metastasis. We continued to investigate the effect of EDIL3
on tumor cell invasion and anoikis. A eukaryotic expression
system suitable for secreted protein synthesis was used to
generate recombinant EDIL3 with high fidelity (Additional
file 3: Figure S3). SMMC-7721 and MHCC-97H, two cell
lines with low basal levels of autocrine EDIL3, were chosen
to undergo functional assays in the presence of EDIL3.
EDIL3 did not affect invasion or proliferation (Additional
file 2: Figure S2B). However, using WST-8 and Caspase3/7
activity assay, we found EDIL3 significantly lowered the
anoikis rate. EDIL3 treatment reduced the Caspase3/7
activity and increased the viability in cancer suspended in
poly-hema coated dishes for long to 72 h (Figure 3A-D).
In soft agar clone formation, EDIL3 also significantly
promoted the anchorage-independent growth in SMMC-
7721 and MHCC-97H cells (Figure 3E). These effects
above are both dose-dependent, with the 50 nM safely
reaching significance.
Figure 2 (See legend on next page.)
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Figure 2 EDIL3 exhibits a unique expression pattern in cell lines. A, detailed analysis of EDIL3 expression in mRNA level, cell lysates and CMs
of 7 HCC and 2 non-HCC cell lines demonstrated an approximate correlation between mRNA and secreted EDIL3 in CMs, whereas EDIL3 in cell
lysates exhibited almost same intensity. Notably, Huh-7 and CSQT-2 exhibited a much higher level of secreted EDIL3. B, ELISA assay testing the
EDIL3 in CMs of 9 cell lines validates the secreted EDIL3 level is approximately correlated with mRNA level. C, Immunofluorescence staining of
EDIL3, F-actin and DAPI in confocal microscope shows EDIL3 is localized within cells and at almost the same intensity in all the 9 cell lines under
test, despite their varied mRNA level.
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LM3 with overexpression vectors. Elevated mRNA of
EDIL3 did not increase intracellular EDIL3 levels in
western blot; however, we did detect an elevation of
autocrine EDIL3 by ELISA and western blot of CMs
(Figure 4A). SMMC-7721 overexpressing EDIL3 exhibited
a significant advantage of anoikis resistance and anchorage-
independence compared with control cells (Figure 4B-E)
without affecting the proliferation and invasion (Additional
file 2: Figure S2C). Importantly, the addition of EDIL3 in
control cells partly mimicked, albeit to a lower degree, these
effect (Figure 4B-E). We obtained similar results in
MHHC-LM3, a cell line that also exhibited a low basal level
of autocrine EDIL3 (Additional file 4: Figure S4A-E).
We tested whether knocking down EDIL3 would cause
the opposite effects. Using two shRNA sequences, we
significantly suppressed the mRNA level of EDIL3, leading
to a decrease in secreted EDIL3 in Huh-7 cells but no
changes in intracellular EDIL3 in control cells (Additional
file 5: Figure S5A). In agreement with the result from
overexpression experiments, the decrease in EDIL3 in CM
increased the caspase3/7 activity, lowered the WST-8
value and inhibited the colonies formed in soft agar, while
adding recombinant EDIL3 partly rescued these inhibitory
effects (Additional file 5: Figure S5B-D).
Taken together, these results indicate that EDIL3,
especially secreted by cancer cells in our current study, is
effective in protecting them from anoikis after suspension,
thus supporting anchorage independent growth.EDIL3 promotes HCC tumorigenesis in vivo
To further elucidate the functional role of anoikis
resistance conferred by EDIL3 in vivo, subcutaneous
tumor formation assays with EDIL3-overexpressing and
control SMMC-7721 were performed in nude mice.
The results clearly indicate that the size of tumor
formed in SMMC-7721 with EDIL3-overexpression is
significantly larger than the control cells in the 2–4
week after subcutaneous implantation (Figure 5A, C).
IHC staining and qRT-PCR confirmed the overexpres-
sion of EDIL3 in cancer cells (Figure 5B, C) and re-
vealed that tumors with high EDIL3 exhibited a much
lower apoptosis rate by TUNEL assay, whereas PCNA,
a proliferative marker, was dominantly positive in
EDIL3-overexpressing tumors but only sporadicallypositive in control tumors (Figure 5D). These results
demonstrate that EDIL3 supports subcutaneous tumor
formation.
Activation of FAK-Src-AKT signaling by EDIL3 ligation is
associated with anoikis resistance
Because EDIL3 is a known ligand of integrins, we first
examined whether HCC cell lines express receptors for
EDIL3, such as integrin αV and α5. All of the cell lines
used in this study expressed these integrins (Additional
file 3: Figure S3B). We then examined the alteration of
integrin-mediated signal pathways that were key to cell
survival upon autocrine EDIL3. Indeed, we observed
that EDIL3 activates signals downstream of integrins.
During the 48 h of suspension, the pro-survival FAK-Src-
AKT signal gradually faded away, suggesting the anoikis
triggered by detachment. However, the FAK-Src-AKT
signal was significantly sustained in EDIL3-overexpressing
cells but tapered much more quickly in control cells
(Figure 6A). The administration of recombinant EDIL3
also elevated these signal pathways, although to a lesser
degree than overexpression (data not shown). However,
pretreating cells with RDG-blocker cilengitide reversed
the activation of FAK-Src-AKT (Figure 6B).Disrupting integrin ligation restores anoikis susceptibility
to HCC
Based on the results above, we continued to examine
weather disrupting the EDIL3/ integrins interaction
could affect the anti-anoikis effect of EDIL3. In first
effort, Cilengitide, an RGD-containing integrinαV
antagonist, almost abrogated the anti-anoikis conferred
by EDIL3 overexpression by lowering the WST-8 value
(and increasing casepase3/7) to the control cells. However,
Cilengitide did not result in an obvious pro-apoptotic
effect on control cells, which have low EDIL3 expression
(Figure 7A). In another effort, silencing of integrin αV by
RNAi also led to a loss of protection of EDIL3. Surprisingly,
the relative caspase3/7 intensity declined significantly with
the down-regulation of integrin αV (Figure 7B); indeed, we
observed similar results in an integrin α5 knock down assay
(data not shown). These results suggest that RGD binding
of integrinαV or integrinα5 is crucial for EDIL3-induced
anti-anoikis and that integrins alone or when unligated
might activate apoptosis in detached cancer cells.
Figure 3 (See legend on next page.)
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Figure 3 Treatment of EDIL3 contributes to anoikis resistance and anchorage-independent growth advantage in HCC. A, Different
concentration of recombinant EDIL3 is used to treat SMMC-7721 suspended in poly-hema coated dishes. It sustains the viability of SMMC-7721 as
demonstrated by caspase3WSt-8 assay in a time and dose dependent manner compared with control protein. B, Recombinant EDIL3 ameliorate
the anoikis compared with control protein in SMMC-7721 as demonstrated by caspase3/7 intensity assay in a time and dose dependent manner.
C-D, MHCC-97H is subjected to the assays same as SMMC-7721 and obtain consistent result. E, Administration of recombinant EDIL3 increases
the anchorage-independent growth of SMMC-7721 and MHCC-97H cells in soft agar compared with control protein in a dose dependent manner.
The assays last for 28 days. *: P < 0.05; **: P < 0.01.
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This study provides a clear expression pattern of one
ECM protein, EDIL3, in clinical samples and highlights
the role of autocrine EDIL3 in the integrin-mediated inter-
action between HCC and ECM, which resulted in an anti-
anoikis and anchorage-independent growth advantage.
Our results also suggest a potential therapeutic strategy
for personalized medicine by targeting ECM-integrin in-
teractions for cancer cells in a subgroup of HCC patients.
In tissue level, EDIL3 is dominantly expressed and se-
creted by the endothelium, acting as a regulator of
vascularization, immunocyte-endothelium adhesion and
platelet microparticle clearance [14,15,26], or by a subset
of macrophages to mediate engulfment [27]. Our data re-
veal that EDIL3 expression is turned on in adult human
normal liver (cells) and is amplified during malignant
transformation, which is different from mouse data,
wherein EDIL3 is undetectable in the liver [15]. The cause
of the up-regulation of EDIL3 in HCC is not clear; how-
ever, there is evidence suggesting that VEGF induces
EDIL3 expression in malignant cells [28] and some in-
flammatory cytokines in endothelium [25]. Therefore it is
possible that EDIL3 is elevated in response to cytokines in
HCC. However, other events, such as HBV incorporation
or epigenetic modifications, may also affect EDIL3
expression. Meaningfully, by analyzing an adequately
sized sample, we demonstrated that when EDIL3 pro-
tein is accumulated to a high level, it is associated with
larger tumor size and more PVTT formation, as well as
greater relapse risk and shorter overall survival, which
is consistent with a previous study, although the previ-
ous report only reached a positive result in overall
survival [20], most likely due to the sample size and
difference in patients selection.
In cell lines, however, EDIL3 demonstrates a unique
expression. By examining multiple HCC cell lines and
normal hepatocyte derived cell line, we find EDIL3 is
expressed by both the normal and malignant cell lines,
suggesting EDIL3 may not be directly linked to the relative
tumorigenicity of HCC cell lines. Interestingly, we reveal
that intracellular EDIL3 protein is observed at almost the
same level despite the large differences in transcription.
This inconsistency in transcription and translation was
explained by the difference in secreted EDIL3. Moreover,
either overexpressing or knocking-down the transcriptionlevel of EDIL3 only affected the secreted EDIL3. Based on
these observations in cell lines and human samples, we
postulate that EDIL3 is maintained in a standby status by
many types of cells in quiescent (or normal) conditions and
is secreted upon elevated transcription in physiologic or
pathophysiological conditions; notably, the secretion is
probably key to its biological functions. However, it will
also be interesting to see the effects of EDIL3 knock-out
in malignancies, and the potential regulation of EDIL3
secretion.
EDIL3 is well documented as an integrin ligand,
modulating a wide range of biological processes that
require integrins, such as integrin αV in angiogenesis
and integrin αL in the neutrophil adhesion cascade
[13,29]. Because integrins such as integrin αV are also
abnormally expressed in HCC [30], we postulated that
EDIL3 may affect HCC cells through integrin ligation
when it is secreted and anchored on the cell mem-
brane, or deposited in the ECM. By overexpressing
EDIL3 or recombinant EDIL3 treatment, we observed
that secreted EDIL3 reduced the likelihood of anoikis
in cancer cells and promoted anchorage-independent
growth, both of which are indispensable for HCC
spreading and PVTT formation, whereas do not affect
proliferation or invasion. Indeed, all of the fresh PVTT
samples in our study exhibited a very high level of
EDIL3 protein, so it is highly possible that tumor cells
bring this protective protein when leaving primary
lesion, thus assisting PVTT formation. Similar strategies
to overcome anoikis have been reported in other types of
cancer, in which another ECM protein, collagen IV, is
expressed [31].
The anoikis is a complex apoptosis process resulted
from cell detachment from ECM or inappropriate cell-cell
adhesion. The lack of ECM contact or the engagement
with inappropriate ECM leads to the activation of anoikis
from death receptors (extrinsic pathway) or mitochondria
(intrinsic pathway) [32]. Integrins on the cell surface are
crucial for anoikis modulation by modulating both the
extrinsic and intrinsic pathway, passing opposite signals
in their ligated or unligated status [21,23,33] or even
independent of their ligation status [34]. The 397FAK-
416Src-473AKT axis is a well-documented pro-survival
pathway in anoikis resistance [32,35-37]. Our results
suggest that this axis is sustained when cancer cells are
Figure 4 (See legend on next page.)
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Figure 4 Overexpression of EDIL3 in SMMC-7721 cells significantly increases the anoikis resistance and anchorage independence. A,
Overexpression of EDIL3 is validated by real-time PCR, western blot and ELISA assay, confirming that the increase in transcription leads to a higher
autocrine EDIL3. B, EDIL3-overexpressing SMMC-7721 forms more clones in soft agar compared with control cells, which can be partly mimicked
by recombinant EDIL3 (50 nM). C, After being suspended for up to 72 h, the overexpressing group demonstrates a high WST-8 value compare to
the control cells at 48 h and 72 h, and administration of recombinant EDIL3(50 nM) in control cells partly mimics the effect induced by EDIL3
overexpression. D, Caspase3/7 intensity assay validate that the difference in cell viability between the two groups is caused by lower apoptosis
induction. E, Annexin V/PI stain by FACS is performed to validate the apoptosis result. EDIL3 overexpression lowers both the early phase and later
phase apoptosis percentage and recombinant protein partly mimics this effect. *: P < 0.05; **: P < 0.01.
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phorylation of all three effectors was partly inhibited when
RGD binding sites were blocked by cilengitide, suggesting
that RGD recognition is critical for this pro-survival
signal. Another interesting finding is that the suppression
of integrin αV (or α5) expression led to a strong anoikis
resistance, suggesting that unligated integrin may trigger
anoikis, which is supported by other studies [38,39].
However, intriguingly enough, integrin αV or α5 expres-
sion by cancer cells is required for invasion and spreading
[40-42]. This seemly contradictory role of integrins
reflects the importance of a suitable interaction between
cancer cells and the microenvironment, or ECM, at the
suitable stage of tumor progression; in this study, an
EDIL3-integrin alliance may be exploited by detached
HCC cells to escape anoikis when cells detach from the
primary lesion, which resulted into a higher success rate
of metastasis.
Finally, a variety or integrin inhibitors has entered
clinical trial of different types of cancers [33,43].
However, the outcomes have fallen short of expecta-
tions, revealing the complexity of integrin function as
discussed above. Therefore, refined patient selection is
required. Cilengitide was initially documented as an
angiogenesis and invasion inhibitor [44]. However, our
preliminary study suggests a potential role of cilengitide
in inhibiting anoikis resistance in EDIL3-overexpressing
HCC, thus pointing to a new potential indication of
integrin inhibitors in HCC and providing a reference
for patient selection.
Conclusion
Our study suggests that high levels of autocrine EDIL3
may contribute to a receptive microenvironment for the
survival of HCC cells and therefore assist cancer cell
progression, which lead to adverse clinical results.
Although other explanations may be concealed in our
current effort, the anti-anoikis conferred by high level of
EDIL3 is an important mechanism for through which
EDIL3 provide protection for HCC cells. Disrupting the
ligation of EDIL3 to integrins via RGD-blockers or
inhibitors in selected patients with high EDIL3 may bear
potential therapeutic value.Methods and materials
Cell culture
The HCC cell line Sk-Hep1 was purchased from the
American Type Cell Culture Collection (ATCC), HuH-7
was purchased from RIKEN Resource Centre, Japan,
SMMC-7721 was purchased from the Cell Bank of the
Chinese Academy of Sciences Cell Bank of Type Culture
Collection. The metastatic HCC cell lines MHCC-97 L,
MHCC-97H and MHCC-LM3 were obtained from the
Liver Cancer Institute, Zhongshan Hospital, Fudan Uni-
versity. The HCC cell line CSQT-2 derived from a portal
vein tumor thrombus (PVTT) has been described else-
where [45]. Human liver epithelial cell line THLE-3 was
purchased from ATCC;. All cell lines except THLE-3 were
cultivated in DMEM (Dulbecco’s modified Eagle medium)
supplemented with 10% (v/v) fetal calf serum at 37°C in a
humidified incubator under 5% CO2 condition. THLE-3
was cultivated in BEGM (Lonza) with the addition of
BEGM bullet kit according to the instruction on ACTT.
Sample information
All samples were collected in Department of Liver Surgery,
Renji Hospital, Shanghai Jiaotong University School of
Medicine. Fresh samples, including tumor tissues and
PVTTs, were obtained from HCC patients during tumor
resection. Normal livers and cirrhotic livers were collected
from healthy liver donors and cirrhosis patients, respect-
ively, during liver transplantation. Approximately 202 HCC
samples were collected from 2004 to 2010 and were con-
structed into tissue microarray (TMA). The median age of
this cohort of patients was 50 years (range 17–73 years).
The majority of patients are HBV-positive (187/202). The
follow-up was ended in December 2012, and the median
period was 33 months (range 2–90 months). All human
samples were obtained with informed consent, and proto-
cols were approved by the ethical review committee of the
World Health Organization Collaborating Center for Re-
search in Human Production (authorized by the Shanghai
Municipal Government).
Quantitative real-time PCR
Total RNA was extracted using Trizol reagent (Takara)
and reverse transcribed using PrimeScript qRT-PCR kit
Figure 5 EDIL3 promotes HCC tumorigenesis in vivo. A total of 1.0 × 106 of EDIL3-overexpressing or control SMMC-7721 cells are
subcutaneously implanted into the right flank of 5 nude mice of each groups. The mice were observed and tumors formed are measured every
week and resected after 6 weeks. A, After 6 weeks, EDIL3-overexpressing group shows relatively larger tumors compare with control group. B,
qRT-PCR of 5 tumors in each group demonstrates a significant elevation in mRNA level. C, Tumor growth curve reveals a shorter latency in the
EDIL3-overexpressing group (2 weeks) vs. the control group (4 weeks) and tumors in the EDIL3-overexpressing group are significantly larger than
control group from 2nd week to 4th week. D, IHC stain in the same region of the tumor confirms the overexpression of EDIL3 and suggests more
active proliferation (PCNA) and lower apoptosis (tunel) upon EDIL3 overexpression. **: P < 0.01.
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PCR analyses were performed with SYBR Premix Ex Taq
(Takara) on a 7300 Real-time PCR system (Applied
Biosystems Inc.), and the primer for EDIL3 was as follows:
forward, GTGAACTGTCGGGTTGTTCTGAG; and re-
verse, 5′-GGTTCCCAAGTGAACATGTCCAT-3′. Theprimers for ACTB were as follows: forward, 5′-
TCACCCACACTGTGCCCATCTACGA-3′; and re-
verse, 5′-CAGCGGAACCGCTCATTGCCAATGG-3′.
The relative expression of EDIL3 was analyzed by the
comparative cycle threshold method (ΔΔCt method),
which was normalized to ACTB.
Figure 6 Sustained activation of FAK-Src by EDIL3 through RGD recognition. A, Western blot and densimetric analysis suggests EDIL3
overexpression sustains the signal intensity of FAK-Src and results in higher AKT phosphorylation within suspended SMMC-7721 cells over
48 hours. The elevated 397p-FAK, 416p-Src and 473p-AKT axis in overexpressing cells compare with control cells exists at most of the time points. B,
Cilengitide (10 μM) reversed the activation of the FAK-Src-AKT axis induced by EDIL3. The signal intensity was examined after 24 h of suspension.
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The HCC samples were handled with T-Per tissue protein
extraction reagent (Thermo Scientific) according to the
manufacturer’s protocol. Total cell protein was obtainedby IP lysis buffer (Beyotime) for further assays. The
secreted proteins in conditional media were collected by
ethanol precipitation. Briefly, when cells grew to approxi-
mately 80% confluence, normal media were replaced by
Figure 7 (See legend on next page.)
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Figure 7 Disrupting integrin-EDIL3 ligation deprives HCC of anoikis resistance induced by EDIL3 in SMMC-7721 and MHCC-LM3. A,
Cilengitide (10 μM) reduces the WST-8 value and increased casepase3/7 of the EDIL3 overexpressing group back to levels of control group, suggesting
a blockage of EDIL3’s effect. There was not any effect observed in the control group in WST-8 and caspase3/7 assay. Both the two cell lines show
consistent results. B, when integrin αV was knocked down to a very low level in both cell lines by two siRNAs (Si2 and Si3), the alteration in WST-8 and
casepase3/7 value of EDIL3-overexpressing cells compared with control cells disappear. Interestingly, the WST-8 value and casepase3/7 intensity results
suggest the overall anoikis significantly declined upon integrin αV silencing in both siRNA knock-down groups compare with si-control group.
**: P < 0.01.
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and 95% ethanol was added and kept overnight. The
precipitated proteins were collected with SDS loading
buffer and underwent standard western blot immediately.
Western blot was performed using SDS-PAGE gel for
proteins separation and nitrocellulose membrane for
proteins blotting. The total volume of protein used in
WB is 50 μg for tissue sample assays, and 30-60 μg in
cell line assays. The signal was detected by the Odyssey
infrared system (LI-COR).
The antibodies used were the following: EDIL3
(ProteinTech), ITGAV (Abcam), p-FAK397 (Cell Signal
Technology), FAK (Abcam), p-Src416 (Epitomics), Src
(Cell Signal Technology), p-AKT473 and AKT (Cell Signal
Technology), StrepII (Abcam), GAPDH (ProteinTech)
and β-actin (Abcam).
Immunohistochemistry stain and analysis
A total of 202 samples of HCC on 2 TMA slices, 3
NLs, 10 HCCs and 6 PVTTs are subjected to IHC.
Paraffin-embedded sections 5 μm thick and TMA were
stained according to standard Immunohistochemistry
(IHC) protocols. Heat-mediated antigen retrieval in
pH 6.0 citric acid was performed. The antibodies used
here were EDIL3 (ProteinTech). The scoring of EDIL3
was performed according to the ratio and intensity of
positive-staining cells: 0-5% scored 0; 6-35% scored 1;
36-70% scored 2; and more than 70% scored 3. The
final score was designated as negative (score 0), positive
(score 1 or 2) and high positive (score 3). These scores
were determined independently by two experienced
pathologists in a blinded manner.
Enzyme-linked immunosorbent assay
HCC cell lines were planted on 10 cm petri dish until 90%
confluence, then were incubated in 3 ml serum free media
for 48 hour. At the end of the incubation period, the
conditional media were harvested and stored at -80C until
use. The secreted EDIL3 in media were quantified using
ELISA kits according to the manufacturer’s instructions
(CUSABio).
Immunofluorescence staining
In cell assay, all the HCC cell lines under tests were
seeded on cover slides in 24-well plates and incubatedovernight. For F-actin staining, cells were incubated with
phalloidin-FITC (Sigma-Aldrich) for 75 minutes at room
temperature. For EDIL3 staining, cells were incubated
with primary antibodies against EDIL3 (Abnova) for
75 minutes at room temperature, followed by an Alexa
Fluor 594-conjugated secondary antibody. In tissue stain-
ing, two samples embedded in paraffin were subjected to
heat-mediated antigen retrieval in pH 6.0 citric acid, and
blocked by 10% BSA. The primary antibodies used are
EDIL3 (Abnova) and CD31 (Abcam) with Alexa Fluor
594-conjugated secondary antibody against EDIL3 and
Fluor 488 against CD31. Immunofluorescence signals
were captured using confocal micro-scopy (LSM 510,
METALaser Scanning Microscope, Zeiss).
Recombinant EDIL3 expression, purification and
characterization
Human EDIL3 (NM_005711 Origene) with the signal
peptide truncated were cloned into the episomal expression
vector pCEP-Pu-Strep II-tag (N-terminal) in-frame with the
sequence of the BM-40 (SPARC/osteonectin) signal peptide
downstream of the CMV promoter, which has been
described elsewhere [46]. Briefly, the expression vector was
transfected into human embryonic kidney 293/Epstein-Barr
nuclear antigen cells (EBNA-293) by Xetrem (Roche). The
cells were screened with puromycin, and the surviving cells
were cultured on a large scale. The culture medium
was collected and centrifuged, and the supernatant was
subjected to the StrepTactin sepharose column (IBA)
for purification. The collected proteins were quantified
and validated by Coomassie Brilliant Blue (CBB) stain-
ing and western blot. The empty vector was applied as
control proteins.
Establishment of stable overexpression or knock-down
cell lines
For the overexpression of EDIL3 in cell lines, the full-length
cDNA of EDIL3 (NM_005711 Origene) was subcloned into
pCDH-CMV-MCS-EF1-Puro vector (System Biosciences).
Lenti-virus was packaged in 293 T cells using Lipofecta-
mine2000 (Invitrogen), and the virus DNA was transduced
into cell lines. For knock-down of EDIL3, short hairpin
RNA (shRNA) sequences (Sh1:5′-CCGGCCCAAGTTTGT
CGAAGACATTCTCGAGAATGTCTTCGACAAACT
TGGGTTTTTG- 3′; Sh2: 5′-CCGGGGAGGTTGCA
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CCTCCTTTTTG- 3′) targeting EDIL3 were cloned
into pLKO.1-puro vectors (Roche). ShRNA-
containing plasmids were packaged into lenti-
viruses and transduced into target cell lines as
above. The efficiency of over-expression or knock-
down was tested by qRT-PCR and western blot.
Anoikis assay
Anoikis was induced by culturing cells in poly-HEMA
coated plates as described by others [47]. Briefly, poly-
HEMA were prepared as a 10 mg/ml solution in ethanol,
which covered completely the petri-dish or plates, then
dried and repeated once. Cells in serum-free medium
were seeded into the coated plates with or without adding
the recombinant EDIL3 at the corresponding concentra-
tion. To avoid survival effects caused by the clumping of
cells, 0.5% methyl cellulose (Sigma-Aldrich) was added
into the medium. At the designated time points, the
suspended cells were collected and subjected to cell viabil-
ity assays by WST-8 kit (Dojindo), apoptosis assays by
Caspase3/7 Glo kit (Promega), and Annexin V/PI staining
on FACS (BD) according to the protocols from the
respective manufacturers.
Anchorage-independent growth assay
Colony formation in soft agar was tested to assay
anchorage-independent growth. Stable overexpressing
EDIL3 cell lines SMMC-7721 and MHCC-LM3 or their
control cells were suspended in the upper layer
consisting of culture medium with 1% FBS and 0.35% agar,
which is above a basal layer of 0.6% agarose in 6-well
plates in a triplicate manner. The cell density was 2,500
cells per well. The soft agars were fed twice a week with
0.3 ml of culture medium. In recombinant EDIL3 treat-
ment assay, the soft agars were fed every 2 days with
serum-free culture medium containing EDIL3 or empty
vector. Colonies were stained with 0.05% crystal violet,
and all the visible colonies were counted by microscopy
after 21–28 days.
Tumorigenesis in vivo
A total of 1.0 × 106 of lenti-vector or lenti-EDIL3 SMMC-
7721 cells were implanted subcutaneously into the right
flank of 5 BALB/c (nu/nu) mice in each group. Tumor
sizes were measured once a week, and mice were sacri-
ficed for the analysis of tumor burden after 6 weeks. All
procedures were performed in accordance with The
Animal Care and Use Committee of Jiaotong University.
The resected mice tumors were fixed in methanol and
embedded in paraffin before being subjected to IHC using
anti-EDIL3 (ProteinTech), anti-PCNA (Abcam) and anti-
TUNEL (Millipore).RGD-blocking assay and knock-down of ITGAV
Cyclic RGD-containing peptide cilengitide (Selleckchem)
or control peptide RGE was used to block the ligation of
EDIL3 to integrins on the surface of HCC cells at a final
concentration of 10 μM. Briefly, the cells was suspended
in Poly-HEMA coated plates and exposed to the peptides
about 3 hours after suspension. Then, the cells were sub-
jected to the assays as described above. SiRNA targeting
ITGAV (Si2: 5′-GCCAGCCAAUUGAAUUUGATT- 3′;
Si3: 5′-CCCAGUUGUAUCUCACAAATT - 3) was used
to knock down the protein level of this integrin and was
confirmed by western blot. After 72 h of transfection, the
cells were subjected to the assays as above.
Statistical analysis
Statistical analyses were performed with SPSS 16.0
software. The association between EDIL3 expression
and clinicopathological parameters was analyzed by
Pearson Chi-Square test. Overall survival and relapse
risk was calculated by the Kaplan-Meier method and
compared by the log-rank test. Statistical significance
was determined by two-tailed Student’s t test for any
differences observed (P < 0.05).
Additional files
Additional file 1: Figure S1. A, The protein level of EDIL3 in NL, CL,
HCC and PVTT run on the same gel was quantified by EDIL3/β-actin
densitometry analysis respectively. The density of NL or CL samples are
significantly lower compare with HCC and PVTT. B, Immunofluorescence
staining of EDIL3, F-actin and DAPI in confocal microscope shows EDIL3
is localized within cells and at almost the same intensity in the cell lines.
Additional file 2: Figure S2. The EDIL3 is widely expressed in other
cancer cell lines. A, The EDIL3 expression pattern in 6 pancreatic cancer, 5
gastric and 2 endometrial carcinoma cell lines showed a difference
mRNA level, while the protein level within cell was almost the same
Neither EDIL3 overexpression or administration affects the invasion or
proliferation of HCC cells. B,C, Neither administration of recombinant
EIDL3 or EDIL3 overexpression led to a change of proliferation or
invasion of SMMC-7721, which are examined by WST-8 assay and
transwell-matrigel invasion assay respectively. Lenti-EDIL3-E2 stands for
monoclonal overexpressing cells.
Additional file 3: Figure S3. A. Validation of purified recombinant EDIL3-
StrepII protein by coomassie blue and western blot. Coomassie blue show a
single brand, which validate the purity of protein. Both the EDIL3 antibody
and StrepII antibody detect a single brand, and the intensity is consistent
with concentration, which further validate the accuracy of the result. B, All
the normal or HCC cell lines express integrinαV as shown in western blot.
Additional file 4: Figure S4. EDIL3 overexpressed by MHCC-LM3
significantly increases the anoikis resistance and anchorage independence.
A, overexpression of EDIL3 is validated by qRT-PCR, western blot and ELISA,
confirming the increase in transcription leads to a higher autocrine EDIL3
whereas no change within cell. B, EDIL3 overexpressing MHCC-LM3 formed
more clones in soft agar compared with control cells, which can be partly
mimicked by recombinant EDIL3 (50nM). C, After being suspended for 72 h,
more cells in overexpressing group survived compared with control cells. D,
caspase3/7 intensity assay validated the difference in survival between two
groups was caused by lower apoptosis. E, Annexin V/PI stain by FACS was
performed to validate the apoptosis result. *: P < 0.05; **: P < 0.01.
Additional file 5: Figure S5. Knocking down EDIL3 in Huh-7 increases
the anoikis and suppresses the anchorage-independent growth. A, knocking
Feng et al. Molecular Cancer 2014, 13:226 Page 16 of 17
http://www.molecular-cancer.com/content/13/1/226down of EDIL3 by 2 shRNA was validated by real-time PCR, western blot
and ELISA, confirming the suppression in transcription leads to a lower
autocrine EDIL3. B, after being suspended for 48 h, both two knock-
down group showed a less survived cell compared with control group.
C, caspase3/7 intensity assay validated the difference in survival is due
to more apoptosis in knock-down group. E, Annexin V/PI stain by FACS
was performed to validate the apoptosis result. *: P < 0.05; **: P < 0.01.
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